Santen, Aerie reach agreement for rights to Rocklatan, Rhopressa in Japan
Santen Pharmaceutical and Aerie Pharmaceuticals have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, according to a press release.
The agreement also includes rights in several other Asian countries.
Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution, Aerie) are already approved by the FDA. In Japan, the first phase 3 study for Rhopressa is in the preparation stage and will likely begin by the end of the year, the release said.
Aerie will receive an upfront payment of $50 million, with sales and development milestones totaling up to $99 million. It will also be eligible for “additional consideration in excess of 25%” of Rhopressa net sales.
Santen is responsible for sales, marketing, pricing decisions, development, commercialization costs and activities of the products in the covered territories, the release said, with the companies collaborating on the upcoming Rhopressa study in Japan.